Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.1252W HIGH $17.42
Volume
3.21 K
Value Traded
24.03 M
Short % Float
7.2%
-0.59%Week
-5.88%1 Month
+15.6%3 Month
+49.8%6 Month
+3.38%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
526.73 M
EPS (TTM)
0.02
P/E Ratio
983.01
Ent. Value
425.97 M
Total Shares
34.71 M
Float Shares
32.10 M
Insiders
7.49%
Institutions
50.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
DCTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Delcath Systems, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Delcath Systems, Inc.
822Total events
2Upcoming
160Tier-1 (high impact)
2008 to 2028Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Delcath management to attend Canaccord Genuity 46th Annual Growth Conference
▲First Patient DosedHEPZATOApprovedTrial
First patient dosed in Phase 2 trial of HEPZATO in liver-dominant metastatic breast cancer
liver-dominant metastatic breast cancersource ↗
▲Quarterly UpdateCorporate
HEPZATO KIT revenue of $27.1 million in Q2 2026
metastatic uveal melanomasource ↗
▲Quarterly UpdateCHEMOSATApprovedCorporate
CHEMOSAT revenue of $2.0 million in Q2 2026
liver cancerssource ↗
▲Quarterly UpdateHEPZATOApprovedCorporate
Approximately 30% growth in HEPZATO volume in Q2 2026 vs Q2 2025
metastatic uveal melanomasource ↗
●R&D DayPresentation
Delcath Systems to participate at H.C. Wainwright 4th Annual BioConnect Investor Conference
◆Poster PresentationCHEMOSATApprovedPresentation
E-poster presentation of safety and feasibility data for M-PHP (CHEMOSAT) in liver-dominant metastatic breast cancer at ESMO Breast Cancer Congress 2026
liver-dominant metastatic breast cancersource ↗
▲Full ResultsClinical Data
Full results from CHOPIN Phase 2 trial published in The Lancet Oncology
metastatic uveal melanomasource ↗
◆Oral PresentationCHEMOSATApprovedPresentation
Dr. Mustafa Ege Seker presents preliminary clinical experience with PHP for uveal melanoma liver metastases
liver metastases from uveal melanomasource ↗
◆Oral PresentationHEPZATOApprovedPresentation
Dr. Eric Wehrenberg-Klee discusses HEPZATO user experience at SIR Innovation Hub
metastatic uveal melanomasource ↗
▲PublicationPresentation
CHEMOSAT Hepatic Delivery System for Melphalan included as recommended liver-directed regional therapy option in ESMO-EURACAN guidelines for uveal melanoma
uveal melanomasource ↗
▲Other Regulator MilestoneCHEMOSATApprovedEx-US Regulatory
CHEMOSAT included as recommended therapy in ESMO-EURACAN guideline
uveal melanomasource ↗
▲Full ResultsClinical Data
Publication of full results from CHOPIN trial in The Lancet Oncology
metastatic uveal melanomasource ↗
▼Equity OfferingCorporate
Repurchased 316,023 common shares for ~$3.0M under $25M buyback program
▲Full ResultsCHEMOSATApprovedClinical Data
Publication of full results from CHOPIN trial in The Lancet Oncology
metastatic uveal melanomasource ↗
●PublicationPresentation
Publication of subgroup analyses from FOCUS study in Journal of Cancer Research and Clinical Oncology
metastatic uveal melanomasource ↗
●PublicationCHEMOSATApprovedPresentation
Publication of long-term retrospective study from University Hospital Tübingen in International Journal of Cancer
metastatic uveal melanomasource ↗
●Oral PresentationPresentation
Management attending BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
◆PublicationPresentation
Publication of subgroup analyses of Phase 3 FOCUS study of HEPZATO KIT in mUM
unresectable metastatic uveal melanomasource ↗
▲Oral PresentationHEPZATOApprovedPresentation
Retrospective data presented at ESMO Breast Cancer 2026 showing 60% hepatic partial response rate
metastatic breast cancersource ↗
▲First Patient DosedHEPZATOApprovedTrial
First patient dosed in global Phase 2 trial of HEPZATO in combination with standard of care
HER2-negative metastatic breast cancersource ↗
▲Full ResultsClinical Data
Publication of subgroup analyses of Phase 3 FOCUS study of HEPZATO KIT in mUM
unresectable metastatic uveal melanomasource ↗
◆Oral PresentationPresentation
Conference call to discuss Phase 2 CHOPIN trial results and financial overview
▲Oral PresentationCHEMOSATApprovedPresentation
Topline results presented at ESMO Congress
metastatic uveal melanomasource ↗
◆Oral PresentationPresentation
Delcath management to attend Canaccord Genuity 45th Annual Growth Conference
▲First Patient DosedHEPZATOApprovedTrial
First patient dosed in global Phase 2 trial of HEPZATO in combination with trifluridine-tipiracil and bevacizumab for liver-dominant metastatic colorectal cancer
liver-dominant metastatic colorectal cancersource ↗
▲Other Regulator MilestoneEx-US Regulatory
Plan to enter into National Medicaid Drug Rebate Agreement
metastatic uveal melanomasource ↗
▲Trial InitiationHEPZATOApprovedTrial
Initiation of Phase 2 trial evaluating HEPZATO in combination with standard of care for metastatic colorectal cancer
metastatic colorectal cancersource ↗
▲Other Regulator MilestoneEx-US Regulatory
Received authorization from EU and UK regulatory authorities for clinical study of Melphalan for Injection Hepatic Delivery System in refractory mCRC
refractory metastatic colorectal cancer with liver dominant diseasesource ↗
▲Enrollment MilestoneTrial
Activated three new U.S. centers in Q2 2025, total 20 active centers
metastatic uveal melanomasource ↗
▲IND ClearanceHEPZATOApprovedIND
FDA clearance of IND for phase 2 trial of HEPZATO in liver-dominant metastatic breast cancer
liver-dominant metastatic breast cancersource ↗
▲Equity OfferingCorporate
Exercise of 1.62 million Series F warrants for $16.2 million funding
▲IND ClearanceHEPZATOApprovedIND
FDA Clearance of IND for Phase 2 Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer
Liver-Dominant Metastatic Colorectal Cancersource ↗
◆Trial InitiationHEPZATOApprovedTrial
Phase 2 Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer Initiated
Liver-Dominant Metastatic Colorectal Cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How DCTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-08-15 | Hepzato (melphalan hydrochloride) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$377M
Pipeline Value
$218M
Commercial Value
Fair Value
Valuation Signal
1
Drugs Scored
1.2x
rNPV / MCap
Top 36%
Micro Cap(rank 238 of 658)
Percentile Rank
Delcath Systems, Inc. carries a moderate pipeline score (41/100), with $943M risk-adjusted pipeline value, led by Hepzato Kit (melphalan HDS) in Metastatic Breast Cancer in the Liver (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $95.4M x 2.3 = $218M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| HEPZATO KIT | $89M | $64M | +38.1% |
| CHEMOSAT | $7M | $6M | +11.8% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepzato Kit (melphalan HDS) Small moleculeMarketedNCT05022901 | Metastatic Ocular Melanoma | Phase 3 | ACTIVE NOT_RECRUITING | 30 | Mar 1, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every DCTH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| melphalan | liver-dominant metastatic breast cancer | 2026-05-07 | hepatic partial response rate: 60%; median overall survival: 6.0 months; percentage alive at last follow up: 33%Read More | Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sylvester John RichardDirector | Grant/Award | 22,500 22,500 held | $0.00 | 05/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DCTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.3 % | 2.34 M | 185.67 K | -56.95% ( -245.58 K) |
DCTH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DCTH ranks across every disease it competes in
Competitive Position is a premium feature
See how DCTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDCTH News
DCTHDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. has announced the granting of equity awards as inducements to four new employees starting in July and August 2026. These awards, approved by the Compensation Committee, are in the form of Restricted Stock Units (RSUs) totaling 34,000. This move reflects the company's commitment to enhancing its workforce in the interventional oncology sector.
Read more →DCTHDelcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems, Inc. announced its participation in two upcoming investor conferences. The Wells Fargo Healthcare Conference will take place on September 10, 2026, in Boston, MA, followed by the H.C. Wainwright 27th Annual Global Investment Conference on September 15, 2026, in New York, NY. This engagement aims to enhance investor relations and showcase their oncology solutions.
Read more →DCTH▲ +22.5%on this news· ran to +36% by day 3
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
Delcath Systems, Inc. reported its financial results for the second quarter of 2026, showing a total revenue of $29.1 million, which is an increase from $24.2 million in the same quarter of 2025. The revenue from the HEPZATO KIT™ also saw a notable rise, reaching $27.1 million compared to $22.5 million in the previous year. This growth highlights the company's ongoing success in the interventional oncology market.
Read more →DCTHDelcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
Delcath Systems, Inc. will attend the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA. The company specializes in interventional oncology, particularly for liver cancers. This participation reflects their ongoing commitment to advancing treatment options in this field.
Read more →DCTHDelcath Systems to Host Second Quarter 2026 Earnings Call
Delcath Systems, an interventional oncology company, announced it will host an earnings call on August 6, 2026, to discuss its second quarter results. The call is scheduled for 8:30 AM Eastern Time. This event highlights the company's ongoing commitment to transparency and investor engagement.
Read more →DCTHDelcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Delcath Systems has commenced its Phase 2 clinical trial for HEPZATO, with the first patient dosed at the European Institute of Oncology in Milan. This trial aims to evaluate the drug in combination with standard care for liver-dominant metastatic breast cancer. The study, named DELUMA, represents a significant step in addressing this challenging condition.
Read more →DCTHDelcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
Delcath Systems has announced two abstracts related to investigator-initiated trials that will be presented at ASCO 2026. The details of these trials-in-progress are expected to provide insights into ongoing research efforts. This announcement highlights Delcath's commitment to advancing cancer treatment options.
Read more →DCTHDelcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Delcath Systems is set to participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference. This event provides a platform for the company to engage with investors and discuss its business strategies. Further details about the conference and Delcath's agenda were not disclosed.
Read more →DCTHDelcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Delcath Systems presented new data on percutaneous hepatic perfusion with melphalan (M-PHP) at the ESMO Breast Cancer Congress 2026. The retrospective analysis involved 15 patients with liver-dominant metastatic breast cancer, showing a 60% hepatic partial response rate. However, safety concerns were noted, with significant adverse events reported. The findings underscore the potential of M-PHP and the need for further studies.
Read more →DCTHDelcath Systems Reports First Quarter 2026 Results and Business Highlights
Delcath Systems reported a total revenue of $25.0 million for Q1 2026, marking an increase from $19.8 million in Q1 2025. HEPZATO KIT revenue also saw substantial growth, contributing $23.3 million. However, the company faced a net loss of $1.1 million, a reversal from the previous year's net income. The publication of the CHOPIN trial results is anticipated to positively influence future prescribing patterns.
Read more →DCTHDelcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems, Inc. will host its first quarter 2026 earnings call on May 7, 2026, at 8:30 AM ET. The call will discuss financial results for the quarter ending March 31, 2026. Delcath is known for its innovative interventional oncology products, including HEPZATO KIT and CHEMOSAT, which target liver cancers.
Read more →DCTHDelcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
Delcath Systems, Inc. has announced that its CHEMOSAT Hepatic Delivery System for Melphalan has been included as a recommended liver-directed regional therapy option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma. This recognition may enhance treatment options for patients suffering from this rare form of cancer. The inclusion underscores the system's potential effectiveness and credibility in clinical settings.
Read more →DCTHDelcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Delcath Systems, Inc. will participate in the Society of Interventional Radiology 2026 Annual Scientific Meeting in Toronto, Canada, from April 11-15, 2026. The company will feature its Hepatic Delivery System in three presentations, highlighting user experiences and preliminary clinical results related to percutaneous hepatic perfusion for liver metastases. This participation underscores Delcath's commitment to advancing treatment options for liver cancer.
Read more →DCTHDelcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
Delcath Systems announced the publication of the CHOPIN trial results in The Lancet Oncology, demonstrating the efficacy of combining percutaneous hepatic perfusion with immunotherapy for metastatic uveal melanoma. The trial showed a significant increase in progression-free and overall survival rates. Despite some safety concerns, the results highlight a promising treatment avenue for liver-dominant cancers.
Read more →DCTH▼ -11.9%on this newsshared move
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
Delcath Systems reported strong financial results for Q4 and full year 2025, with total revenue reaching $20.7 million in Q4 and $85.2 million for the year. The company highlighted robust growth in procedure volume and positive operating cash flow, despite increased expenses. Looking ahead, Delcath anticipates continued momentum in 2026 driven by expanded treatment centers and positive clinical data.
Read more →DCTHDelcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
Delcath Systems, Inc. will host a conference call on February 26, 2026, to discuss its fourth quarter and full year results for 2025. The call is set to begin at 8:30 AM Eastern Time. Delcath specializes in interventional oncology, offering products like HEPZATO KIT and CHEMOSAT for liver cancer treatment.
Read more →About Delcath Systems, Inc.
Headquarters566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804
BIOPHARMAWATCH ELITE PLUS
Trade the next DCTH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime